NovoCure LimitedNVCR stock score: 44/100
$10.69 · -0.37% · Scored Nov 19, 2026
- Technical
- 23
- Fundamental
- 50
- News
- —
The reading
NovoCure (NVCR) scores 44 out of 100, which reads weak, higher than 34% of Healthcare stocks and 32% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 50, technicals 23.
Among the fundamentals, Price Target at 100 and Revenue Quality (Quarterly) at 100 score highest, while Earnings Growth (5-Year) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 10 and contrarian oscillators 71 — a split worth reading before trusting the technical total.
Since Aug 22, 2026 the composite has ranged from 33 to 48, and it is down 2 points over the period.
About NovoCure
NovoCure (NVCR) is an oncology company that sells Tumor Treating Fields, a therapy that uses alternating electric fields delivered through arrays placed on the skin to disrupt cancer cell division. Patients wear the portable device for most of the day at home. Its products include Optune Gio for glioblastoma, an aggressive brain cancer, Optune Lua for non-small cell lung cancer and pleural mesothelioma, and Optune Pax for locally advanced pancreatic cancer, approved for use alongside chemotherapy. NovoCure sells mainly in the United States, Germany and Japan, along with other countries in Europe and Asia. It earns money mainly by billing insurers and government health programs a monthly fee for each patient on therapy, which covers the device, arrays and support services.
NovoCure’s therapy is used alongside chemotherapy, radiation and immunotherapy rather than replacing them, and it competes for patients and payer budgets with cancer drugs from companies such as Merck, AstraZeneca and Roche. Its edge rests on being the only company with approved Tumor Treating Fields products, along with patents and data from several late-stage trials. Investors who follow NVCR stock tend to watch active patients on therapy and new prescriptions. Uptake of Optune Lua and Optune Pax is closely followed. Reimbursement decisions, results from ongoing trials, gross margins, operating costs and convertible debt are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward NVCR’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
50Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.
EV/Revenue compares the whole company's value, debt included, with its sales.
Holding it back
5-year earnings growth evaluates long-term profit trajectory and consistency.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
19Pulling it up
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
- RSI (14)94
Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Holding it back
Performance versus SPY compares the stock's returns to the S&P 500 index.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Simple Moving Average (100-period) provides a longer-term perspective on price trends.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 32 | 1 |
| Daily | 19 | 3 |
| Weekly | 19 | 2 |
| Monthly | 29 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 44 |
| Nov 18, 2026 | 45 |
| Nov 17, 2026 | 45 |
| Nov 16, 2026 | 45 |
| Nov 15, 2026 | 46 |
| Nov 14, 2026 | 46 |
| Nov 13, 2026 | 45 |
| Nov 12, 2026 | 43 |
| Nov 11, 2026 | 33 |
| Nov 10, 2026 | 33 |
| Nov 8, 2026 | 35 |
| Nov 7, 2026 | 35 |
| Nov 6, 2026 | 34 |
| Nov 5, 2026 | 37 |
| Nov 4, 2026 | 40 |
| Nov 3, 2026 | 36 |
| Nov 2, 2026 | 35 |
| Nov 1, 2026 | 35 |
| Oct 30, 2026 | 34 |
| Oct 29, 2026 | 34 |
| Oct 28, 2026 | 36 |
| Oct 27, 2026 | 37 |
| Oct 26, 2026 | 36 |
| Oct 25, 2026 | 37 |
| Oct 24, 2026 | 37 |
| Oct 23, 2026 | 37 |
| Oct 22, 2026 | 40 |
| Oct 21, 2026 | 42 |
| Oct 20, 2026 | 41 |
| Oct 19, 2026 | 38 |
| Oct 18, 2026 | 35 |
| Oct 17, 2026 | 35 |
| Oct 16, 2026 | 35 |
| Oct 15, 2026 | 36 |
| Oct 14, 2026 | 35 |
| Oct 13, 2026 | 36 |
| Oct 12, 2026 | 37 |
| Oct 11, 2026 | 37 |
| Oct 10, 2026 | 37 |
| Oct 9, 2026 | 36 |
| Oct 8, 2026 | 35 |
| Oct 7, 2026 | 36 |
| Oct 6, 2026 | 38 |
| Oct 5, 2026 | 37 |
| Oct 4, 2026 | 37 |
| Oct 3, 2026 | 37 |
| Oct 2, 2026 | 38 |
| Oct 1, 2026 | 40 |
| Sep 30, 2026 | 40 |
| Sep 29, 2026 | 40 |
| Sep 28, 2026 | 38 |
| Sep 27, 2026 | 39 |
| Sep 26, 2026 | 39 |
| Sep 25, 2026 | 40 |
| Sep 24, 2026 | 42 |
| Sep 23, 2026 | 42 |
| Sep 22, 2026 | 44 |
| Sep 21, 2026 | 42 |
| Sep 20, 2026 | 43 |
| Sep 19, 2026 | 43 |
| Sep 18, 2026 | 44 |
| Sep 17, 2026 | 43 |
| Sep 16, 2026 | 41 |
| Sep 15, 2026 | 41 |
| Sep 14, 2026 | 41 |
| Sep 13, 2026 | 39 |
| Sep 12, 2026 | 39 |
| Sep 11, 2026 | 40 |
| Sep 10, 2026 | 39 |
| Sep 9, 2026 | 40 |
| Sep 8, 2026 | 44 |
| Sep 7, 2026 | 47 |
| Sep 6, 2026 | 47 |
| Sep 5, 2026 | 47 |
| Sep 4, 2026 | 46 |
| Sep 3, 2026 | 46 |
| Sep 2, 2026 | 47 |
| Sep 1, 2026 | 46 |
| Aug 31, 2026 | 46 |
| Aug 30, 2026 | 47 |
| Aug 29, 2026 | 47 |
| Aug 28, 2026 | 46 |
| Aug 27, 2026 | 47 |
| Aug 26, 2026 | 48 |
| Aug 25, 2026 | 47 |
| Aug 24, 2026 | 45 |
| Aug 23, 2026 | 47 |
| Aug 22, 2026 | 46 |
Key facts
- Market cap
- $1.2B
- Sector
- Healthcare
- Industry
- Medical Devices
- Beta
- 1.08
- Risk grade (1–10)
- 4
- Next earnings
- Oct 29, 2026
Medical Device peers
| Company | Market cap | Score |
|---|---|---|
| PRCT PROCEPT BioRobotics | $1.5B | 51 |
| CNMD CONMED | $1.4B | 57 |
| TNDM Tandem Diabetes Care | $1.2B | 38 |
| SIBN SI-BONE | $1.1B | 59 |
| ATEC Alphatec | $1.1B | 52 |
| IART Integra LifeSciences Holdings | $1.1B | 43 |
Questions
What is NVCR's stock rating today?
NVCR scores 44/100 (Weak) as of Nov 19, 2026: technical 23, fundamental 50. Scores are recomputed every night.
What does NovoCure do?
NovoCure (NVCR) is an oncology company that sells Tumor Treating Fields, a therapy that uses alternating electric fields delivered through arrays placed on the skin to disrupt cancer cell division. Patients wear the portable device for most of the day at home.
Is NVCR stock a buy?
The score is not a buy or sell recommendation. A 44 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the NVCR score calculated?
99 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/nvcr/"><img src="https://stocksscores.com/stocks/nvcr/badge.svg" alt="NVCR stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/nvcr/)